Samik Pharmaceutical Company LTD. (KOSDAQ:014950)
South Korea flag South Korea · Delayed Price · Currency is KRW
16,210
-450 (-2.70%)
At close: Jan 29, 2026

KOSDAQ:014950 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023
Period Ending
Sep '25 Dec '24 Dec '23
Operating Revenue
58,87555,85751,229
Other Revenue
--0-
58,87555,85751,229
Revenue Growth (YoY)
14.93%9.04%-
Cost of Revenue
16,90417,11917,359
Gross Profit
41,97138,73833,870
Selling, General & Admin
35,71432,61228,847
Research & Development
2,1231,9431,757
Amortization of Goodwill & Intangibles
5.022556.12
Other Operating Expenses
261.52302.34287.89
Operating Expenses
38,24735,06031,073
Operating Income
3,7253,6782,796
Interest Expense
-9.1-12.26-18.53
Interest & Investment Income
78.3186.69198.16
Currency Exchange Gain (Loss)
1.71.751.36
Other Non Operating Income (Expenses)
190.61213.21147.23
EBT Excluding Unusual Items
3,9864,0673,124
Gain (Loss) on Sale of Investments
308.4300.14298.32
Gain (Loss) on Sale of Assets
2.779.50.07
Asset Writedown
--23.8-
Pretax Income
4,2974,3533,423
Income Tax Expense
1,030830.99453.53
Net Income
3,2673,5222,969
Net Income to Common
3,2673,5222,969
Net Income Growth
10.04%18.62%-
Shares Outstanding (Basic)
777
Shares Outstanding (Diluted)
777
Shares Change (YoY)
1.61%0.15%-
EPS (Basic)
458.09501.00423.00
EPS (Diluted)
458.09501.00423.00
EPS Growth
8.29%18.44%-
Free Cash Flow
2,0553,543874.05
Free Cash Flow Per Share
288.12503.91124.52
Gross Margin
71.29%69.35%66.11%
Operating Margin
6.33%6.59%5.46%
Profit Margin
5.55%6.31%5.80%
Free Cash Flow Margin
3.49%6.34%1.71%
EBITDA
5,1115,0294,074
EBITDA Margin
8.68%9.00%7.95%
D&A For EBITDA
1,3861,3511,278
EBIT
3,7253,6782,796
EBIT Margin
6.33%6.59%5.46%
Effective Tax Rate
23.97%19.09%13.25%
Advertising Expenses
-565.36753.43
Source: S&P Global Market Intelligence. Standard template. Financial Sources.